Fermeture du portail BDSP le 1er juillet 2019. En savoir plus...

1. The costs of treating breast cancer in the United Kingdom : Implications for screening.

   Réf. 168318 Article - En anglais

   INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, vol. 14, n° 2, 1998, pages 277-289, 39 réf., ISSN 0266-4623, GBR

   WOLSTENHOLME (J.L.), SMITH (S.J.), WHYNES (D.K.)

   University of Nottingham. GBR

   Total treatment costs by stage at diagnosis are estimated for a sample of breast cancer patients.

   At 4 years, stage 4 cancers emerge as being more expensive to treat than those at earlier stages, although this difference fails to achieve significance when expected lifetime costs are considered.

   The inclusion of treatment cost estimates in a screening model indicates that screening may increase expected treatment costs by a marginal amount, although the model also suggests that the cost-effectiveness ratio of breast cancer screening might be better than had originally been thought.

   Mots-clés BDSP : Cancer, Sein, Thérapeutique, Coût, Homme, Royaume Uni, Europe, Analyse coût efficacité, Dépistage, Economie santé, Glande mammaire [pathologie]

   Mots-clés Pascal : Tumeur maligne, Glande mammaire, Traitement, Stade clinique, Coût, Homme, Royaume Uni, Europe, Analyse coût efficacité, Dépistage, Economie santé, Glande mammaire pathologie

   Mots-clés Pascal anglais : Malignant tumor, Mammary gland, Treatment, Clinical stage, Costs, Human, United Kingdom, Europe, Cost efficiency analysis, Medical screening, Health economy, Mammary gland diseases

   Notice produite par :
   Inist-CNRS - Institut de l'Information Scientifique et Technique

   Cote : 98-0305552

   Code Inist : 002B20E02. Création : 27/11/1998.

   ---

   Transférer dans Zotero Comment se procurer ce document ?